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Patients with poor and intermediate prognosis metastatic germ-cell tumours (MGCTs) are at a significant risk of relapse after standard
platinum-based chemotherapy. Novel treatment regimens are required to improve survival. Dose intense, alternating combinations of
drugs with known activity in germ-cell tumours represents one approach. In all, 43 patients with IGCCCG intermediate/poor
prognosis MGCT were treated with a dose intense regimen alternating bleomycin, vincristine, cisplatin (BOP) with bleomycin,
etoposide, cisplatin (BEP) to a maximum of three cycles. Data were collected on the maintenance of dose intensity, toxicity,
response, progression-free (PFS) and overall survival (OS). The complete response rate was 58%; a further 7% of patients being
rendered disease free by resection of viable residual tumour. With a median follow-up of more than 4 years in surviving patients, 3-
year OS and PFS rates of 81% (95% CI: 66–91%) and 72% (95% CI: 56–83%) are seen, respectively. Bleomycin, vincristine, cisplatin
(BOP)/bleomycin, etoposide, cisplatin (BEP) was well tolerated, with 86% of patients completing all planned courses. Toxicity was
predominantly haematological with common toxicity criteria grade III neutropenia in 90% of patients. Cisplatin neuropathy and
bleomycin-induced pulmonary toxicity represented the most significant nonhaematological toxicity. Bleomycin, vincristine, cisplatin
(BOP)/bleomycin, etoposide, cisplatin (BEP) represents a practicable, well-tolerated, dose intense chemotherapy regimen with
significant activity in intermediate and poor prognosis MGCT.
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The introduction of effective cisplatin-based chemotherapy regi-
mens since the 1970s, has converted metastatic germ-cell tumours
(MGCTs), with a very poor prognosis, into the paradigm of a
curable cancer. Despite the development of strategies that
successfully treat the majority of patients with MGMT, there
remains a small but significant group of patients destined to die of
their disease. Considerable effort has thus been directed at refining
the treatment of individual patients depending on their risk of
relapse or treatment failure, predicted from prognostic factors
present at the time of diagnosis. The development of a prognostic
factor-based staging system by the International Germ Cell Cancer
Collaborative Group (IGCCCG, 1997) has provided a standardised
set of prognostic indicators that identify intermediate prognosis
and poor prognosis groups.
Although the salvage of relapsed MGCT is increasingly
successful (De Bono et al, 2000), strategies to improve the survival
from intermediate or poor prognosis MGCT have focused
predominantly on first-line chemotherapy regimens. Standard
therapy for nonmetastatic, nonseminomatous germ-cell tumours
at high risk of relapse, and for good prognosis MGCT has, in
general, consisted of a combination of cisplatin, etoposide and
bleomycin (BEP). Approaches to improve on this have been to
increase cisplatin dose (Ozols et al, 1983); add or substitute novel
chemotherapeutic agents (de Wit et al, 1999); alternate treatment
regimens between combinations of active agents (Bower et al,
1997; Germa et al, 1999); increase the dose intensity by shortening
intervals between treatments (Horwich et al, 1989; Horwich et al,
1997); use myeloablative doses of active agents in combination
with bone marrow or peripheral stem-cell rescue (Motzer et al,
1997; Decatris et al, 2000); or combinations of these methods. To
date, none of these have proven superior to standard BEP therapy
in prospective randomised trials. However, we believe that an
intensive, alternating schedule represents one of the most
promising approaches.
The aim of this study was, therefore, to determine the toxicity
and effectiveness, in terms of the response and survival of
alternating BOP/BEP, a novel dose intense combination che-
motherapy regimen, based on individual components with which
there was already considerable experience.
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Patients
Patients aged p65 years with IGCCCG intermediate or poor
prognosis MGCT were eligible for this study. Histological
diagnosis of primary testicular or extragonadal germ-cell cancer
was required, although diagnosis on the strength of elevated serum
tumour markers (aFP, bhCG, LDH) alone was allowable if tissue
for histology was unobtainable. Minimum characteristics for
intermediate or poor prognosis disease were defined as: testis/
retroperitoneal primary and AFP X1000ngml
 1; or HCG
X5000IUl
 1; or LDHX1.5 upper limit of normal. Prior
chemotherapy or radiotherapy was not allowed and disease-
specific surgery was restricted to orchidectomy or biopsy of
tumour. Patients were required to have adequate renal function
(calculated GFR X40mlmin
 1) prior to trial entry.
Ethics review
The protocol was approved by the local research ethics committee
of each participating institution. Written informed consent was
obtained from each patient.
Treatment
The BOP/BEP regimen is shown in Figure 1. An initial course of
BOP was followed on day 10 by a course of standard 5-day BEP (de
Wit et al, 2001). The BOP cycle was repeated again on days 31 and
62, with BEP on days 41 and 72.
In the BOP regimen, cisplatin at 50mgm
 2 was administered
over 4h on each of 2 days with a standard pre- and
postchemotherapy hydration regimen, and after ensuring an
adequate urine output (4100mlh
 1). For BEP, cisplatin at
20mgm
 2 was given daily for 5 days by the same method.
Intravenous bleomycin (30000U) was administered as a 12h
infusion in 500ml of normal saline.
Treatment modifications
A total white blood cell count (WBC) o1.5 10
9l
 1 or platelets
o50 10
9l
 1 on the first day of any treatment cycle resulted in a
treatment delay. Blood counts were repeated every 3 days until
these thresholds were exceeded and treatment was given. A delay
of more than 2 weeks resulted in withdrawal from the study.
Cisplatin dose was reduced by 25% for a WBC of 1.5–
2.0 10
9l
 1 and/or platelets of 50–75 10
9l
 1 on the day of
treatment. At blood counts higher than these cisplatin was given at
full dose.
A combination of WBC 1.5–2.0 10
9l
 1 and platelets 76–
100 10
9l
 1 or WBC 42.1 10
9l
 1 and platelets 50–75 10
9l
 1
on the day of treatment reduced etoposide dose by 50%. For WBC
1.5–2.0 10
9l
 1 and platelets 4100 10
9l
 1 or WBC
42.1 10
9l
 1 and platelets 76–1000 10
9l
 1, the reduction of
etoposide dose was 25%.
Prophylactic use of white cell colony-stimulating factors was not
permitted, although they could be used at the discretion of the
treating doctor in the event of prolonged or complicated
neutropenia.
Creatinine clearance was calculated (Cockcroft and Gault
formula) at the start of each treatment. Cisplatin and bleomycin
were withheld if the calculated clearance was o40mlmin
 1.I f
renal function recovered to 440mlmin
 1, cisplatin was restarted
at 75% and bleomycin at 100%. Severe skin toxicity (Xcommon
toxicity criteria (CTC) grade 2) or signs of lung toxicity were
indications for stopping bleomycin.
Assessment of response and toxicity
A total of three complete cycles of BOP and BEP was planned for
each patient. A complete response was classified as normalisation
of tumour markers with no clinical or radiological evidence of
residual disease at the completion of treatment. Clinical or
radiological evidence of residual tumour, despite normal markers,
was an indication for explorative surgery with resection and
histological examination of the residual masses. The absence of
viable tumour cells, or the presence of mature teratoma only, in the
resected tumour was also classified as a complete response. An
incomplete response to treatment was defined as the presence of
residual viable cancer in resected material postchemotherapy and/
or the failure of tumour markers to normalise by the end of three
cycles BOP/BEP. Such patients received additional treatment at the
discretion of the investigator. Treatment failure was defined as a
plateau in the decline of tumour markers (at a level 420IUl
 1)o n
3 successive weekly samples, or evidence of progressive disease (a
rise in markers on three successive samples over a 4-week period
or development of new metastatic lesions).
Treatment-related toxicity was monitored weekly through the
regimen and at regular intervals after completion. Pulmonary
toxicity was assessed by review of patient’s symptoms and clinical
examination. Pulmonary function tests and CT scans were used to
further investigate new symptoms or signs. Symptoms of
neuropathy were recorded and graded at each visit with clinical
assessment if required. Audiometry was performed at baseline and
repeated in the event of patients complaining of tinnitus or hearing
loss.
Statistical method
The study was designed as a pilot to determine the feasibility of
this regimen in terms of the degree of grade 3/4 toxicity. The
primary end point chosen was the percentage of patients
developing grade III/IV mucositis during their chemotherapy,
with o5% deemed as acceptable, 415% too toxic and in-between
uncertain. It was calculated that at least 40 evaluable patients
would be required to give a 90% chance of detecting an increase in
the rate of grade 3/4 mucositis from 5 to 15%.
The duration of progression-free survival (PFS) and overall
survival (OS) were calculated from the start of chemotherapy on an
intention-to-treat basis. Actuarial survival curves were calculated
using the Kaplan–Meier method. Toxicity was graded using the
CTC.
RESULTS
Patient characteristics
A total of 43 eligible patients, from four regional testicular cancer
treatment centres in the UK, were entered into this study between
March 1995 and October 1999. The majority of patients were
entered by two centres (51 and 37%), with differences in
BOP      BEP  BOP  BEP  BOP  BEP 
0    10             31      41           62    72 
Days from start of treatment
BOP cycle
Bleomycin  30000 U, i.v.  day 1 
Vincristine  2 mg, i.v.  day 1 
Cisplatin     50 mg m−2, i.v.
BEP cycle
Bleomycin  30000 U, i.v.   day 1 
Bleomycin  30000 U, i.m.  days 8 + 15
Etoposide days 1 − 5 
Cisplatin days  1  − 5 
days 1+2 
20 mg m−2, i.v. 
100 mg m−2, i.v. 
Figure 1 BOP/BEP chemotherapy regimen.
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entry into study. The characteristics of the 43 eligible patients are
summarised in Table 1.
In all, 37 (86%) patients received all three cycles of BOP and BEP
as planned, with 243 cycles of chemotherapy completed within the
total cohort of patients. The reasons for not completing BOP/BEP
chemotherapy included: psychological problems; ototoxicity; renal
toxicity; pulmonary toxicity; early surgical resection of disease;
and disease progression. Alternative chemotherapy was adminis-
tered in all but one patient who stopped trial treatment early.
Maintenance of dose intensity
Despite the dose intense nature of the BOP/BEP regimen, only 11
(5%) of 243 cycles of chemotherapy were administered outwith 2
days of the intended start date. Of these delays, only five can be
directly ascribed to treatment, with late recovery of haematological
toxicity responsible for the majority of these. Of the patients, 34
(79%) received all chemotherapy on the dates determined by
protocol.
During the course of their treatment 24 patients (56%) required
a reduction in the dose of at least one of the cytotoxic agents in the
BOP/BEP regimen. Most commonly, this was due to bleomycin
toxicity, seen in 23 patients. Figure 2 shows the common forms of
bleomycin toxicity observed and the percentage of the total
planned dose omitted due to toxicity. Two patients required
reductions in the dose of cisplatin in view of a fall in creatinine
clearance.
Response to treatment
In all, 25 patients (58%) achieved a complete response to BOP/BEP
chemotherapy, 14 of which were initially intermediate prognosis
patients and 11 were of poor prognosis. Five patients (four
poor and one intermediate prognosis) had an incomplete response
to chemotherapy. In four cases this was due to the presence of
viable tumour in resected residual disease. Of the three with
complete resection of residual tumour, one patient is currently
alive and disease free, one died of surgical complications and one
of disease recurrence without further chemotherapy. One patient
had an incomplete resection of viable tumour, received salvage
chemotherapy with high-dose carboplatin/etoposide/ifosfamide,
but subsequently died from his disease. Markers failed to
normalise, without obvious residual disease, in the fifth case and
the patient subsequently died of relapsed disease without having
further chemotherapy.
There was one treatment failure in an intermediate prognosis
patient in whom markers initially fell but then started to rise again
during chemotherapy.
In all, 12 patients were nonevaluable for response in that,
although their markers had returned to normal with chemother-
apy, there was a residual mass observed at CT scanning that was
not amenable to surgical evaluation. Of these patients, five have
relapsed and required further treatment while five remain alive
and progression free. One patient died of treatment-related toxicity
but with no evidence of active disease.
In all, 10 patients have progressed after completion of
chemotherapy, all of whom have received salvage chemotherapy.
Currently, four of these patients are alive and free of disease.
Survival
As of June 2003, the median follow-up period for the 34
living patients is 4.9 years (range 2.2–7.1 years). The estimated
proportion alive at 3 years is 81% (95% CI: 66–91%).
For the intermediate prognosis group, the figure is 79% (95% CI:
57–91%), whereas for the poor prognosis group it is 84% (95%
CI: 59–95%). The actuarial OS for intermediate and
poor performance patients is shown in Figure 3. Relapse-free
survival (RFS) for all patients at 3 years was estimated at 72% (95%
CI: 56–83%). Data for intermediate and poor prognosis groups are
seen in Figure 4.
Of the 42 patients evaluable for survival, nine have died to
date; six from malignant disease, one from toxicity directly
related to BOP/BEP chemotherapy (pulmonary fibrosis), two
from complications arising after salvage therapy (renal
failure during neutropenic sepsis; abdominal haemorrhage after
surgery).
Table 1 Patient characteristics
Patients 43
Age at diagnosis (years): median (range) 27 (17–53)
No. of patients (%)
Site of primary tumour
a
Testis 36 (84%)
Retroperitoneum 1 (2%)
Mediastinum 2 (5%)
Abdomen 2 (5%)
Other
b 2 (5%)
Histology
MTT (Malignant teratoma trophoblastic) 2 (5%)
MTU (Malignant teratoma undifferentiated) 13 (30%)
MTI (Malignant teratoma intermediate) 4 (9%)
MTD (Malignant teratoma differentiated) 3 (7%)
Other
c 13 (30%)
Unknown
d 8 (19%)
(International Germ Cell Cancer Collaborative Group)
IGCCG prognostic category
Intermediate 24 (56%)
Poor 19 (44%)
aIn several cases, the primary biopsy of a nontesticular mass provided a tissue
diagnosis, while an ultrasound of the testis revealed primary tumour. These have been
included as testicular primary.
bTwo patients in whom neck nodes were positive for
tumour but site of primary teratoma not determined.
cMixed seminoma/teratoma or
undifferentiated tumours with elevated tumour markers.
dHistology not obtainable
but elevated tumour markers diagnostic.
0−25%
26−50% 51−75%
Marrow
Skin
Lung
Other
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Figure 2 Reduction in bleomycin dose intensity due to toxicity.
Percentage of dose of bleomycin omitted due to toxicity in patients
receiving BOP/BEP chemotherapy.
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The major toxicity was haematologic with CTC grade 3/4
neutropenia experienced by 39 patients (90%) at some time
during the course of their chemotherapy (Table 2). Anaemia and
thrombocytopenia (CTC grade 3/4) occurred in 30 and 33% of
patients, respectively.
In all, 13 patients required hospitalisation on 18 occasions for
pyrexia associated with neutropenia. Five patients received
haemopoietic growth factors (G-CSF) on a total of 10 occasions
due to prolonged neutropenia or neutropenic sepsis. No septic
deaths were recorded on trial chemotherapy. All other episodes
resolved with appropriate antibiotic and supportive treatment.
In general, nonhaematological toxicity was mild and recovered
quickly on completion of chemotherapy. The incidence of
mucositis, which was the primary end point of the trial, was 7%
grade 3 and no grade 4. Grade 4 biochemical toxicity (reduced
Na
þ,K
þ,M g
2þ) and grade 3 nausea, pulmonary and cutaneous
toxicity was observed in a minority of patients. Two patients
experienced a fall in creatinine clearance sufficient to omit
cisplatin, which was subsequently reintroduced at 75% of full
dose. Cisplatin-induced neurotoxicity was expected with this
regimen, and Table 3 shows the incidence of toxicity greater than
CTC grade 2.
In 14 patients, significant toxicity persisted for 6 months or
longer after treatment ended. This was predominantly neurosen-
sory in the form of ototoxicity (tinnitus; hearing loss) or peripheral
neuropathy (Table 3). Two patients described peripheral vasos-
pasm on exposure to cold and two had radiological and/or
physiological evidence of pulmonary fibrosis (bleomycin lung).
Nine patients (none of whom received salvage chemotherapy) have
indicated symptoms of residual neurosensory toxicity at review 2–
4 years postchemotherapy.
As the risks of infertility (through oligospermia) were con-
sidered significant with the doses of cisplatin used in this regimen,
sperm storage was offered to all patients prechemotherapy if
practicable. Although the determination of fertility postchemother-
apy was not routinely undertaken, at least one patient had severe
oligospermia more than 2 years after treatment. Additional
problems with posttreatment fertility were also encountered in
the form of retrograde ejaculation after retroperitoneal lymph
node dissection.
DISCUSSION
Despite the development of strategies that successfully treat the
majority of patients with advanced or metastatic germ-cell
tumours (MGCT), there remains a small but significant group
destined to die of their disease. The IGCCCG staging system for
MGCT (IGCCCG, 1997) identifies intermediate and poor prognosis
patients with 5-year progression-free survival rates of 75% and up
to 53%, respectively. Although salvage chemotherapy can cure a
proportion of patients after first relapse, the development of more
effective first-line chemotherapy regimens for patients in poor
prognostic groups remains one of the main aims of research in this
field.
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Figure 3 Overall survival. Percent OS of intermediate and poor
prognosis patients by Kaplan–Meier curve. Number of patients available
for assessment at each time point is shown.
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Figure 4 Percent PFS of intermediate and poor prognosis patients by
Kaplan–Meier curve. Number of patients available for assessment at each
time point is shown.
Table 2 Haematological toxicity
Number of patients (%)
CTC grade III CTC grade IV
Granulocytopenia 4 (10%) 35 (83%)
Thrombocytopenia 8 (19%) 6 (14%)
Anaemia 10 (24%) 3 (7%)
Maximum grade of haematological toxicity experienced by patients receiving
bleomycin, vincristine, cisplatin (BOP)/bleomycin, etoposide, cisplatin (BEP).
CTC¼common toxicity criteria.
Table 3 Neurotoxicity of the BOP/BEP regimen
No. and % of patients
with toxicity CTC
grade 2 or 4
No. and % of patients
with toxicity
lasting 41 year
Sensory neuropathy 3 (7%) 3 (7%)
Motor neuropathy 1 (2%) 0
Ototoxicity 13 (30%) 3 (7%)
Frequency of clinically significant or persistent neurotoxicity arising with bleomycin,
vincristine, cisplatin (BOP)/bleomycin, etoposide, cisplatin (BEP). CTC¼common
toxicity criteria.
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prognosis nonseminomatous MGCT is treatment with four cycles
of a combination of BEP (Bosl et al, 1998). Attempts to improve
upon this regimen, in terms of response and OS, have utilised a
number of approaches, one of which has been to increase the dose
intensity of treatment regimens containing drugs with established
single-agent activity in germ-cell tumours. Two different forms of
dose intensive regimens have been developed. (a) Induction
therapy, in which several cycles of a dose intensive, relatively
nonmyelotoxic, induction regimen are administered prior to the
more myelotoxic drug combination. (b) Alternating therapy, using
an intensive alternating schedule of myelotoxic and nonmyelotoxic
drug combinations.
The original BOP/BEP regimen (Horwich et al, 1989) used BOP
weekly as an induction regimen over a 4-week period before
changing to one cycle of 5-day BEP followed by two cycles of EP
(bleomycin being omitted). Bleomycin, vincristine, cisplatin given
on weeks 1 and 3 was similar to that given in the current study,
although bleomycin was 15000U. Bleomycin, vincristine, cisplatin
on weeks 2 and 4 used bolus cisplatin at 40mgm
 2 and a 5-day
continuous infusion of 75000U bleomycin. The total duration of
chemotherapy was 13 weeks. Patients in this study were ‘high risk’
as determined by the Royal Marsden Hospital staging system. In
all, 74% of evaluable patients displayed a complete response to this
chemotherapy and at a median of 2 years follow–up, 85%
displayed no evidence of relapse. A further adaptation of this
induction-type regimen has also been studied in the phase II
setting. C-BOP-BEP (Horwich et al, 1997; Christian et al, 2003)
consists of BOP weeks 1 and 3, carboplatin (AUC 3mgml
 1 min)
plus reduced dose BOP weeks 2 and 4, vincristine and bleomycin
weeks 5 and 6 then BEP weeks 7, 10 and 13. Data on 54 patients
with IGCCCG poor prognosis MGCT treated with this regimen
over an 11-year period have been published recently (Christian
et al, 2003). The 5-year OS and RFS rates were 87.6 and 83.2%,
respectively. The most frequent toxicity was myelosuppresion and
the only toxic death was as a result of bleomycin-induced
pulmonary fibrosis. A phase II study of the BOP/VIP-B regimen,
in which ifosfamide is added to the BEP component, treated 94
patients with MRC poor prognosis features (Lewis et al, 1992). The
overall CR rate was 70% and the 2-year PFS was 63%. However, in
the only randomised study to date of an induction regimen dose
intense therapy, when compared to standard BEP in 380 patients,
BOP/VIP-B showed greater toxicity but no improvement in
response or OS (Kaye et al, 1998).
A dose intense, alternating schedule regimen, POMB/ACE
developed at the Charing Cross Hospital in London has been used
to treat patients with nonseminomatous MGCT since 1977. In a
retrospective analysis of 20 years experience with this regimen
(Bower et al, 1997), patients were classified according to the
IGCCCG system. In all, 31% were of poor prognosis and 14% of
intermediate prognosis prior to chemotherapy. The 3-year OS rates
for these groups were calculated to be 75 and 88%, respectively.
Toxicity was comparable to that published for BEP. Other centres
have also had experience with POMB/ACE (Cullen et al, 1988;
Husband and Green, 1992), but its advantage over standard BEP
has never been tested in a randomised trial. BOMP/EPI is a
modification of POMB/ACE, in which POMB is alternated with a
modified VIP regimen. This has been used in a number of centres
in Spain and over a 10-year period 38 patients, retrospectively
classified as IGCCCG poor prognosis, were treated (Germa et al,
1999). In these patients, the CR was 49% and with a median of 41
months follow-up estimated 2-year OS and PFS were 64 and 58%.
The current study shows that a dose intense regimen, of
alternating cycles of BOP and BEP, is well tolerated and produces
good response rates, PFS and OS in patients with intermediate and
poor prognosis MGCT. The CR rate of 58% and overall 3-year PFS
of 72% (95% CI: 56–83%) compare favourably with the results
from the previously mentioned dose intense studies. The analysis
of the results for intermediate and poor prognosis patients
suggests that most of the improvement is observed in those with
a poor prognosis (3-year PFS of 68% compared to 5-year PFS of
between 41 and 53% in the IGCCCG data). With a median follow-
up of almost 5 years for living patients, the predicted OS at 3 years
is 81% (95% CI: 66–91%), with no significant difference between
intermediate and poor prognosis groups. This is similar to the
POMB/ACE survival but better than that for BOMP/EPI.
The dose intense features of the alternating BOP/BEP regimen,
arising principally through the increased frequency of cisplatin
administration, were maintained with the vast majority of patients
receiving all chemotherapy and on the protocol-determined dates.
Loss of dose intensity from reductions in drug doses occurred in
56% of patients, but mainly due to the omission of bleomycin as a
consequence of toxicity. However, the significance of this is
unclear as five of the six patients who received less than 50% of the
intended dose of bleomycin had complete responses. All the
patients who had an incomplete response to chemotherapy
received less than the full intended dose of BOP/BEP (one omitted
cycle of BEP and five patients with from 6 to 50% of total
bleomycin dose omitted).
Do the results of this study help in determining the optimum
treatment for intermediate or poor prognosis NSMGCT? It is
interesting to speculate as to why the benefits of this dose intense
regimen appear to be predominantly in those patients with poor
prognosis disease. It may be that with more extensive disease,
there are a greater proportion of tumour cells with reduced
sensitivity to chemotherapy and that the increased dose intensity
of BOP/BEP allows less time for these cells to re-establish
themselves between cycles as compared to standard BEP.
The results of this study are similar to those seen in the other
phase II studies of dose intense alternating chemotherapy
regimens. In light of the recently updated results of the
prospectively collected data on C-BOP/BEP (Christian et al,
2003), the dose intense nature of BOP/BEP given by either regimen
appears, in the phase II setting, to offer significant benefits in the
treatment of poor prognosis MGCT compared to historical
controls. Any optimism, in terms of improved outcomes in poor
prognosis disease that these studies generate is, however, tempered
by the negative results of the one randomised trial of this form of
therapy to date (Kaye et al, 1998).
Is it sufficiently important to know the place of dose-intensified
chemotherapy regimens, such as BOP/BEP, in the treatment of
poor prognosis MGCT to justify randomised studies? The relative
rarity of this group of patients makes conducting clinical trials
difficult. In addition, other novel approaches are currently
undergoing evaluation. The ability of high-dose chemotherapy
with autologous stem-cell rescue (ASCR) to salvage heavily
pretreated patients with relapsed MGCT (Beyer et al, 1997) has
led to the examination of this approach as a possible first-line
treatment in poor prognosis patients. A number of nonrandomised
studies (Motzer et al, 1997; Bokemeyer et al, 1998; Decatris et al,
2000) have shown the practicability and tolerability of such an
approach, with OS appearing better than the corresponding figure
from the IGCCCG ‘test’ data. One randomised study of first-line
high-dose chemotherapy has been performed (Chevreau et al,
1993), and this failed to show any benefit for the high-dose
approach. However, the results of this study are difficult to
interpret as the high-dose arm of this study had a lower dose
intensity than the standard-dose arm. A recent multivariate and
matched-pair comparison of poor prognosis patients receiving
first-line high-dose VIP chemotherapy and those receiving
standard-dose BEP or VIP suggests a significant improvement in
PFS and OS for the high-dose approach (Bokemeyer et al, 1999a).
Hopefully, the benefits of this approach will be made a little clearer
on completion of a number of randomised clinical trials such as
the United States intergroup study of BEP 4 vs BEP 2 followed
by high-dose chemotherapy and ASCR.
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tion into combination chemotherapy protocols offers another
approach to improving survival in this group of patients.
Paclitaxel (Motzer et al, 1994; Bokemeyer et al, 1996) and
gemcitabine (Bokemeyer et al, 1999b; Einhorn et al, 1999)
are two such agents and currently promising data from initial
studies of Paclitaxel added to BEP (T-BEP) (de Wit et al, 1999)
have resulted in an EORTC randomised study in intermediate
prognosis MGCT comparing this regimen to BEP (EORTC protocol
30983).
The inevitable outcome of the studies into high-dose che-
motherapy and combinations involving new drugs will be to
present a range of treatment options for this group of patients
requiring comparison in randomised trials. Determining the true
value of dose intense alternating chemotherapy regimens as
compared to standard BEP at this point in time could either
determine a new standard regimen for this group of patients or
remove one of the potential variables from future trials. A Phase III
trial comparing C-BOP/BEP to standard BEP is planned in the
United Kingdom, which may, hopefully, answer this question.
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